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A recognized hazard of administering blood transfusions to patients
with panreactive warm autoantibodies is that alloantibodies may be
masked. Studies have shown the incidence of underlying
alloantibodies to be 30 to 40 percent. Adsorption procedures can
be used to remove autoantibodies and allow detection and
identification of underlying alloantibodies. This study contains data
from 126 patients referred to the Red Cell Immunohaematology
laboratory at the National Blood Service, Newcastle upon Tyne,
United Kingdom. These patients were from the northeast of
England, a population for which data have not previously been
reported. Samples identified as containing panreactive warm
autoantibodies were subjected to adsorption procedures (95 by
alloadsorption and 31 by autoadsorption). Absorbed sera were then
tested to identify underlying alloantibodies. Of 126 samples, 39
(31%) contained a total of 61 RBC alloantibodies; 15 (12%)
contained 2 or more antibody specificities; and 14 (11%) contained
alloantibodies not found within the Rh or Kell blood group systems.
Antibodies identified included the following specificities: E (19), D
(9), c (7), C (6), S (5), Fya (3), Jka (2), Jkb (2), K (2), Kpa (2), Fyb, Cw, N,
and f (ce). This study reinforces the value of adsorption studies,
whether using autologous or allogeneic RBCs, when panreactive
warm autoantibodies are present. In addition, this study confirms
that it is not appropriate in these cases simply to issue blood which
is “least incompatible” or Rh phenotype- and K antigen-matched.
Immunohematology 2005;21:122–125.
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One of the recognized hazards of administering
blood transfusions to patients with panreactive warm
autoantibodies is the failure to detect clinically
significant alloantibodies that may be masked.1,2
Traditionally, some blood banks have had policies of
crossmatching and issuing blood that is “least
incompatible” or “as compatible” as the patient’s own
RBCs, or they have issued blood that is Rh phenotype-
and K antigen-matched.3 Several methods may be used
to remove free autoantibody from the patient’s plasma
to allow the detection and identification of any
underlying alloantibodies.4,5 Adsorption,whether using
autologous or allogeneic enzyme-treated RBCs, is the
method of choice within the National Blood Service
(NBS) in the United Kingdom. British Committee for
Standards in Haematology guidelines recommend that
these techniques be used in such cases.6 This study
was performed over 18 months in the Red Cell
Immunohaematology laboratory at the NBS in
Newcastle. The region has 18 National Health Service
(NHS) hospital blood banks, serving a population of 2.9
million.
Materials and Methods
Our alloadsorption method uses at least two sets of
strongly papain-treated donor RBCs selected to have
complementary expression of important RBC antigens.
It is our usual practice to use Group O,rr,K– and Group
O, R1R1, K– RBCs, one RBC sample being Jk(a–b+) and
the other being Jk(a+b–). Reagent RBCs for adsorption
were obtained from the UK NBS central reagents unit.
Autoadsorption uses the patient’s papain-treated RBCs.
Alloadsorption was performed on more cases as
there was a limited supply of patients’ RBCs to use to
perform autoadsorption, due to severe anemia or low
sample volumes. Serial adsorptions were performed by
incubating 1 mL of the patient’s plasma with 1 mL of
the papain-treated packed RBCs at 37°C; the absorbed
plasma was then retrieved by centrifugation. A
maximum of 4 aliquots of allogeneic RBCs, or typically
2 aliquots of autologous RBCs, were used for this
process. The number of autoadsorption procedures
was dependent on the volume of RBCs available from
the patient sample. Absorbed plasma was then
investigated to detect and identify any underlying
alloantibodies, using reagent RBCs suspended in low-
ionic-strength red cell preservative solution (RCPS;
Inverclyde Biologicals, UK) by tube IAT. Where
possible, phenotype studies were used to confirm that
the identified antibodies were alloantibodies.
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Results
Samples from 130 individual patients were referred
for investigation of panreactive autoantibodies by
autoadsorption or alloadsorption procedures. Data
from four samples in which we failed to successfully
remove the autoantibody were omitted from this study.
Alloadsorption procedures were performed on 95
samples and autoadsorption procedures on 31
samples. Thirty-nine of 126 samples (31%) contained a
total of 61 RBC alloantibodies (Table 1); 87 samples
(69%) contained no underlying alloantibodies. Fifteen
samples (12%) contained two or more specificities
(Table 2). Fourteen samples (11%) contained
alloantibodies with specificities for antigens outside
the Rh or Kell blood group systems.
Of the 61 alloantibodies identified, all but 4 (anti-
Kpa [2], anti-N [1], and anti-Cw [1]) would require the
selection of antigen-negative RBCs for crossmatching in
the UK.6 Of 95 alloadsorbed samples, 33 (35%)
contained alloantibodies, whereas 6 of 31 (19%)
autoadsorbed samples contained alloantibodies.
All but six antibodies (anti-Fya [3], anti-Kpa [2], and
anti-Fyb [1]) were confirmed as alloantibodies, using
phenotyping studies. Phenotyping studies were not
undertaken for these six patients as their RBC samples
had strongly positive DATs. With only typing reagents
requiring the use of AHG available and without a local
procedure for removing autoantibody for typing, test
results would be unreliable. These six antibodies were
therefore assumed to be probable alloantibodies.
Autoantibodies of these specificities are rarely
reported.
Discussion
Limitations and advantages of the adsorption
procedures
1.Alloadsorption
Alloadsorption procedures were preferentially
performed in the cases described, but a number of
factors must be borne in mind when interpreting
results. Alloadsorption procedures require a minimum
of two individual RBC samples with a complementary
antigenic profile at key antigens, in our study, Rh, K, Jka,
and Jkb antigens, and at least 2 mL of available patient
plasma or serum. Papain treatment of the adsorption
RBCs removes enzyme-labile antigens, effectively
rendering the RBCs negative for such antigens. By this
procedure we ensured that underlying alloantibodies
such as anti-S, -s, -Fya, -Fyb, -M, and -N remained behind
after adsorption. We acknowledge that many workers
have found that the s antigen is not readily destroyed.7
Although not every batch of reagent RBCs is
specifically tested for antigen destruction, the process
was thoroughly validated when introduced by the UK
NBS reagents unit. Although no patients in this study
were found to have underlying anti-s at the time of
collating data, the patient referred to in Table 2 with
anti-C, -Fya, and -Jkb did subsequently produce an
underlying anti-s. The enzyme treatment usually
increases the uptake and removal of autoantibody,
although there were some exceptions to this in our
study (four patients) when autoantibody removal was
less effective.
Our standard protocol does not include the use of
e– adsorption RBCs. In our experience the benefits of
including RBCs of the R2R2 phenotype are outweighed
by the practical difficulties of obtaining suitable RBCs
Table 1. Underlying alloantibody specificities
















Table 2. Multiple alloantibody specificities




Anti-E, -Fya, -Jka 1
Anti-S, -N 1
Anti-Fyb, -f(ce) 1
Anti-c, -E, -K, -Fya 1
Anti-C, -Fya, -Jkb 1
Anti-D, -C, -E, -S 1
Anti-E, -K, -Jka 1
Anti-C, -Jkb 1
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and the increased volume of plasma required.
However, RBCs of the R2R2 phenotype are used when
the initial investigation suggests they may be useful.
The policy of matching the Rh phenotype of the donor
units to patients with autoantibodies decreases the risk
of an underlying alloanti-e causing a transfusion
reaction.
Recently transfused patients may give misleading
or inconclusive Rh phenotyping results. In such cases
it is important to establish the transfusion history and
make an individual assessment of the most appropriate
Rh phenotype to select. Where possible it is good
practice to prospectively establish the extended
phenotype of patients likely to be multiply transfused.
Alloadsorption procedures carry the risk that an
alloantibody to a high-prevalence blood group antigen
can be adsorbed by the procedure and not detected
when screening or matching blood. We believe our
findings show that it is better to carry out the
adsorption procedures, being aware of this risk, than
not to adsorb at all. We have experience of one case
(not included in this study) where an underlying anti-
Vel was not detected following alloadsorption (data not
published).
2.Autoadsorption
Autoadsorption uses the patient’s own RBCs to
remove autoantibody so that underlying alloantibodies
can be tested for. The advantages of autoadsorption are
that it does not remove any alloantibodies and it
requires adsorption of only a single aliquot of patient’s
plasma, considerably reducing the volume required.
The number of tests performed is also reduced since
the tests need not be carried out in duplicate, or
triplicate as in the case of alloadsorptions.
Autoadsorption is not without its problems,
however. The patient’s RBCs often are heavily coated
with antibody, with reduced capacity for further
antibody uptake. Patients may also be anemic,
sometimes very anemic, with few RBCs available for
autoadsorption. In our experience, anything less than
two equal-volume (RBCs:plasma) adsorptions does not
remove sufficient autoantibody to be of investigative
value. The relatively large amount of plasma available
from anemic patients lends itself more to
alloadsorption.
Autoadsorption is inappropriate for the recently
transfused patient. If the procedure is inadvertently
applied to samples from such patients there is a risk
that alloantibodies may be adsorbed in vitro onto
transfused RBCs. Our protocol for patients transfused
within the last 3 months is to perform alloadsorption
and to prepare an eluate to detect alloantibodies bound
in vivo.8
Transfusion practices
Transfusion in the presence of panreactive warm
autoantibodies can be a complicated and dangerous
proposition.9 In our study, adsorption techniques
excluded the presence of alloantibodies in 69 percent
of our patients. In the patients found to have
alloantibodies, adsorption studies allowed the selection
of appropriate RBCs for transfusion. In this group, Rh
and Kell phenotype matching alone would have
exposed 14 patients (11%) to the risk of a significant
transfusion reaction.
We believe this study reinforces the value of
adsorption studies when panreactive warm
autoantibodies are present and concurs with the
findings of similar studies. Our findings also show that
it is not appropriate in these cases simply to issue RBCs
that are “least incompatible” or Rh phenotype- and K
antigen-matched.
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